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A B S T R A C T
Introduction and objectives: Trypanosoma cruzi infection has been shown to induce humoral autoimmune
responses against host antigens tissues. Particularly, antibodies cross-reacting with myocardial antigens
may play a role in the development of the severe forms of chronic Chagas disease. The aim of this study
was to determine the association between clinical stage of the disease and the presence of
autoantibodies in patients with chronic Chagasic disease.
Methods: We performed a cross-sectional study in T. cruzi-seropositive patients divided into 3 groups
according to the classic classiﬁcation of chronic Chagas heart of Storino et al. All participants underwent
complete clinical examination and their sera were used to measure autoantibody levels.
Results: All patients had detectable levels of anti-p2b and anti-B13 autoantibodies but none had anti-
Na-K-ATPase antibodies. No association was observed between electrocardiographic conduction
disturbances and autoantibody levels. Patients with chronic Chagas disease stage III had the highest
levels of anti-B13 antibodies and a high risk of mortality score, showing a clear association between
disease stage and this score.
Conclusions: Anti-B13 antibodies were signiﬁcantly higher in chronic Chagas disease stage III patients,
suggesting that these antibodies may be involved in disease progression and that they might be a useful
marker of poor prognosis in terms of heart compromise. Our results also reveal an important correlation
between the level of anti-B13 autoantibodies and symptomatic heart failure and/or dilated
cardiomyopathy.
 2013 Sociedad Espan˜ola de Cardiologı´a. Published by Elsevier Espan˜a, S.L. All rights reserved.
Valoracio´n de anticuerpos con reactividad cruzada pato´geno-hue´sped
en pacientes con diferentes estadios de cardiopatı´a chaga´sica cro´nica
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R E S U M E N
Introduccio´n y objetivos: La infeccio´n por Trypanosoma cruzi induce una respuesta autoinmunitaria
humoral contra diferentes antı´genos del hue´sped. En especial, los anticuerpos que presentan reactividad
cruzada con antı´genos del miocardio tienen un papel importante en el desarrollo de las formas graves de
la cardiopatı´a chaga´sica cro´nica. En este trabajo se analiza la asociacio´n del estadio clı´nico de la
enfermedad con la presencia de autoanticuerpos en pacientes con cardiopatı´a chaga´sica cro´nica.
Me´todos: Estudio transversal con pacientes con serologı´a positiva para enfermedad de Chagas,
categorizados en tres grupos segu´n la clasiﬁcacio´n de cardiopatı´a chaga´sica de Storino et al. Se realizo´ a
todas las personas incluidas un examen clı´nico completo y se usaron las muestras de suero para
cuantiﬁcar los autoanticuerpos.
Resultados: Todos los pacientes presentaron cantidades detectables de anti-p2b y anti B13; el anti-
Na-K-ATPasa fue negativo en todos los casos. No se hallo´ asociacio´n signiﬁcativa entre las alteraciones
electrocardiogra´ﬁcas y los valores de autoanticuerpos. Los pacientes con cardiopatı´a chaga´sica en
estadio III presentaron mayor concentracio´n de anti-B13 y riesgo de mortalidad alto, lo que muestra una
clara asociacio´n entre el estadio de la enfermedad y la puntuacio´n de mortalidad.
Conclusiones: La concentracio´n del autoanticuerpo anti-B13 fue signiﬁcativamente mayor en los
pacientes con cardiopatı´a chaga´sica en estadio III, lo que indica que este anticuerpo puede estar
involucrado en la progresio´n de la enfermedad y podrı´a usarse como marcador de mal prono´stico
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INTRODUCTION
Chagas disease, a parasitic infection caused by the protozoan
Trypanosoma cruzi, affects at least 8-10 million people throughout
South and Central America. Sporadic cases have also been reported
in the United States and Europe. The major complications of this
disease are mega syndromes involving the gastrointestinal tract
or/and the heart. Chronic Chagas disease (CCD) is the most
common manifestation, affecting about 30% of individuals infected
with T. cruzi. Severe heart disorders, such as rhythm or conduction
abnormalities, as well as a speciﬁc dilated cardiomyopathy or
thromboembolic episodes, may cause approximately 50 000
deaths annually.1,2
The mechanisms underlying the pathogenesis of Chagas disease
are complex and multifactorial,3,4 with immune responses to
parasite antigens,5,6 autoimmune processes,7–9 and the inﬂamma-
tory response accompanying these reactions being likely to
be involved.10–15 A humoral autoimmune response due to the
molecular mimicry displayed by some parasite proteins is one of
the mechanisms involved in the pathogenesis of Chagas disease.
Among the several autoantibodies that have been described,
anti-p2b and anti-B13 have been shown to play a pathogenetic
role in the development of heart tissue lesions, both in humans and
in animal models.16 Anti-p2b antibodies cross-reacting against the
b1 adrenergic receptor have been involved in murine models of
cardiac alterations, such as electrocardiographic abnormalities
and myocyte apoptosis.17–23 Cross-reactivity is attributed to the
antigenic acidic epitope present on the C-terminal end of the p2b,
named R13 (EEEDDDMGFGLFD), which shows a similarity to the
AESDE acidic motif on the second extracellular loop of the b1
adrenergic receptor.24 An assessment of anti-p2b antibodies in
chagasic patients in different stages yielded no conclusive results
as to their involvement in CCD.25,26 B13 antigen was shown to
promote an autoantibody cellular response to cardiac myosin
because of the sequence homology to B13 protein epitope
(AAAGDK) of human cardiac myosin heavy chain hexapeptide
(AAALDK).16,27,28 A study in patients with CCD reported a high
prevalence of anti-B13 antibodies in patients with dilated
cardiomyopathy,25 but the correlation of their levels with the
degree of CCD involvement was not explored.
Recently, antibodies against Na + /K + pump ATPase were
associated with dilated idiopathic cardiomyopathy and electro-
cardiographic conduction disturbances.29,30 Interestingly, the
expression of a Na+/K+ pump ATPase by T. cruzi has been described
as a mechanism of adaptation from the extracellular to the
intracellular cycle.31 As Na+/K+ pump ATPase has a human-parasite
highly conserved amino acid sequence, autoantibodies against this
protein might play a role in CCD pathogenesis due to a molecular
mimicry mechanism triggered by this protein.
The present study was designed to evaluate the presence of
anti-p2b, anti-B13 immunoglobulins, and the still unexplored
anti-Na+/K+ pump ATPase antibody in patients with CCD. The
possible association between serum levels of these antibodies and
the degree of cardiac compromise was assessed and the risk of
mortality score was also determined.
METHODS
Study Population and Subject Evaluation
We performed a cross-sectional study in 80 patients with a
positive serological test for T. cruzi. Diagnosis of Chagas disease was
established according to the recommendation of the World Health
Organization with 2 different tests (ELISA and indirect hemaggluti-
nation or indirect immunoﬂuorescence) yielding positive results.32
Patients were divided into 3 groups according to the CCD
classiﬁcation of Storino et al.33 All individuals were recruited at
the clinical service of the Iturraspe Hospital (Santa Fe, Argentina),
and underwent a complete clinical examination, including the
following tests: full blood count, glucose, potassium, creatinine,
blood urea nitrogen, electrocardiogram, chest and abdominal X-ray,
and echo Doppler cardiography. The echocardiograms were
performed according to Acquatella.34 Exclusion criteria included
the presence of 2 or more risk factors for coronary artery disease or
established disease, a history of other cardiac diseases, renal
disturbances, thyroid disease or any other systemic complaints,
as well as treatment with anti-T. cruzi compounds or immunosup-
pressive drugs. The study received ethical approval from the Ethics
Review Board of the Universidad Nacional del Litoral. Informed
consent was obtained from all patients.
According to the above-mentioned classiﬁcation, we included:
a) 30 individuals with CCD stage I (ie, with normal radiological
studies, electrocardiogram and echocardiogram); b) 25 patients
with CCD stage II (ie, with electrocardiographic changes such as left
anterior divisional block, right bundle branch block, total
atrioventricular block, left or right bundle branch block, complex
ventricular arrhythmias, and block of the anterosuperior division
of the left branch), and c) 25 patients with CCD stage III (ie, with
clinical heart failure and/or dilated cardiomyopathy by echocar-
diogram. Clinical heart failure was deﬁned according the 2012 g
Guidelines for the diagnosis and treatment of acute and chronic
heart failure of the European Society of Cardiology.35 All patients in
this group had a diagnosis of heart failure and none was receiving
speciﬁc treatment for this condition at the time of inclusion.
A control group of 10 patients was included. These patients had
dilated cardiomyopathy and heart failure due to hypertension/
coronary artery disease.
Protein Expression and Puriﬁcation
Eschericia coli BL21(DE3) cells bearing the plasmidic construc-
tions pET-32a/p2b, pET-32a/B13 were grown overnight in LB
medium, supplemented with 0.1 mg  mL/1 ampicillin at 37 8C,
with agitation. Protein expression was induced in 1 mM isopropyl-
b-D-thiogalactopyranoside and was puriﬁed with a Ni-nitrilotria-
cetic acid column (GE), as described elsewhere.36 E. coli BL21(DE3)
respecto a la afeccio´n cardiaca. Los resultados revelan tambie´n una importante correlacio´n entre el
anti-B13 y la insuﬁciencia cardiaca sintoma´tica y/o la cardiomiopatı´a dilatada.
 2013 Sociedad Espan˜ola de Cardiologı´a. Publicado por Elsevier Espan˜a, S.L. Todos los derechos reservados.
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cells bearing the plasmidic constructions pET28a/TcENA (as Na+/K+
pump ATPase) were induced by incubating the cells in 1 mM
isopropyl-b-D-thiogalactopyranoside. The bacterial cells were lysed
by sonication and were precipitated by centrifugation at 10 000g
for 10 min at 4 8C. The resulting precipitate was solubilized with
8 mol UREA, incubated with TALON Metal Afﬁnity Resin (BD
Biosciences; San Jose, California, United States) and dialyzed, as
described by Iizumi et al.31
Antibody Measurement
Serum samples were obtained by conventional venipuncture,
and antibodies were measured by immunoassay (ELISA). Microtiter
plates were coated with 0.5 mg of the speciﬁc antigen in 0.05 M
carbonate-bicarbonate buffer, pH 9.6 and were incubated overnight
at 4 8C. Plates were blocked with 5% bovine serum albumin and were
incubated with a 1:100 dilution of human serum in duplicate. Plates
were read at 450 nm in an ELISA reader (BioRad). All serum
samples were evaluated in duplicate, with the result of the test
being the mean optical density value of these simultaneous
assessments. In each plate, 6 negative controls (healthy individuals
seronegative for T. cruzi), were simultaneously assayed.36 ELISA-
negative standard cutoff values were calculated as the mean optical
density of the negative serum samples plus 2 standard deviations.
Antibody levels were expressed as an index that represents the ratio
between the optical density of the sample and the optical density of
the negative standard cutoff. This index is referred to as IODN (index
of the optical density of autoantibodies in relation to the negative
control). An IODN1 was considered negative.36–38
Mortality Score
The risk score for predicting death in Chagas heart disease39,40
was applied in all patients. Patients were included into low- and
high-risk groups because there were no intermediate-risk patients.
Statistical Analysis
Data were analyzed with MedCalc version 12.2.1. Normal
distributions of the continuous variables were tested by the
Kolmogorov-Smirnov method. The data are expressed as means
(standard deviation) or median and interquartile range. Groups
were compared in relation to age, antibody levels, and CCD stages.
The Chi-square test or Fisher’s exact test was used for categorical
variables and one-way analysis of variance (Student-Newman-
Keuls test for all pairwise comparisons) was used to compare the
means of IODN values and age among the groups deﬁned by CCD
stage. Multiple binary logistic regression models were used to
assess the impact of variables that were associated (P<.05) with
heart failure in Chagas disease. Confounders and independent risk
factors were included in the ﬁnal logistic regression model. A
receiver operating characteristic curve was constructed to explore
whether the IODN of antibodies was useful to discriminate among
patients with different CCD stages. A P value of <.05 was
considered signiﬁcant.
RESULTS
General Population
The mean age of sampled individuals was 55 (12.4) years; 56%
were women. There were no between-group differences in age or
sex distribution. Patients in CCD stage III were unaware of being
infected with T. cruzi until they were admitted to the hospital
because of heart failure. Only 12 patients with CCD stage I and II
knew they had Chagas disease. The remaining CCD individuals
were diagnosed on the basis of a screening test because of positive
epidemiology for Chagas disease.
Twelve patients with CCD stage II and 6 patients with CCD stage
III had hypertension and were receiving enalapril. All patients in
the control group were also hypertensive and were being treated
with angiotensin-converting-enzyme inhibitors plus b-blockers.
Systolic blood pressure was signiﬁcantly lower in stage I
individuals than in the remaining groups (Kruskall Wallis test,
P=.0042).
The characteristics of the patients in each group and the
distribution of the antibodies are summarized in Table 1.
Electrocardiographic Disturbances
The most frequent electrocardiographic changes in CCD stage II
and III were left anterior divisional block with right bundle branch
block (n=12), right bundle branch block (n=7) and atrial
ﬁbrillation associated with right bundle branch block (n=7).
Sinus bradycardia was present in 4 patients with CCD stage
II with sinus bradycardia, whereas 2 individuals with CCD stage III
had third degree atrioventricular block requiring pacemaker
implantation. Changes in the control group of patients with
dilated cardiomyopathy were as follows: atrial ﬁbrillation (n=4),
left ventricular hypertrophy (n=3), atrial ﬁbrillation and right
bundle branch block (n=2), and left anterior divisional block and
right bundle branch block (n=1). There was no association
between electrocardiographic conduction disturbances and
hypertension or IODN values for anti-p2b and anti-B13 anti-
bodies. There were no statistically signiﬁcant differences in the
occurrence of pathological electrocardiogram tracings between
patients with CCD (stage II and III) and the control group.
Echocardiographic Findings
Four individuals in the CCD II group had apical septal
hypokinesis without diastolic or systolic disturbance and
2 patients had concentric ventricular hypertrophy. Among the
25 individuals with CCD III, 53% had globally dilated cardiomyop-
athy with reduced ejection fraction, 30% had left atrial enlarge-
ment and abnormal left ventricular relaxation with diastolic
heart failure, and 17% had concentric ventricular hypertrophy
with diastolic disturbance. In the control group, 7 patients had
hypokinesis of the left ventricular walls associated with enlarged
left cavities and reduced ejection fraction, 2 patients had globally
dilated cardiomyopathy, and the remaining patient had apical
septal hypokinesis associated with abnormal left ventricular
relaxation and diastolic heart failure.
As expected, hypertension was associated with concentric
ventricular hypertrophy (P=.04).
Antibodies
All patients with Chagas disease had detectable levels of anti-
p2b (2007 to 11207) and anti-B13 (1950 to 13525) autoantibodies,
whereas none of them exhibited anti-Na-K-ATPase antibodies. All
patients in the control group had negative results. Antibody levels
did not correlate with age, sex distribution, or additional variables
such as hypertension or enalapril treatment.
Comparison of anti-p2b antibodies revealed no intergroup
differences in the CCD group, whereas patients with CCD stage
III had the highest values of IODN for anti-B13 antibodies
M.H. Vicco et al. / Rev Esp Cardiol. 2013;66(10):791–796 793
Author's personal copy
(F ratio=37.32; P<.001) (Fig. 1). This group showed a clear
association with heart failure and a high risk of mortality score
(Fisher’s exact test P<.001).
There were no statistically signiﬁcant differences between the
degree of cardiomyopathy by echocardiogram and the IODN of
autoantibodies. When hypertensive patients were excluded, we
observed that levels of IODN of anti-B13 antibodies increased with
progression of pathological echocardiographic signs (Fig. 2). In
addition, patients with dilated cardiomyopathy and reduced
ejection fraction had an increased level of IODN of anti-B13
compared with those without this alteration (P<.001) in the
populations serologically positive for Chagas disease. Patients with
a high mortality score had higher levels of IODN anti-B13
compared with low-risk individuals (P<.001).
A multiple binary logistic regression was conducted to predict
clinical heart failure using the categorical variables of hyperten-
sion, gender, smoking, and alcohol consumption, and the
continuous variables of age, level of IODN anti-p2b and IODN
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Figure 1. Levels of index of the optical density of autoantibodies in relation to the
negative control of anti-B13 according to the degree of chronic Chagas disease
and in the control group. Lines represent the means (standard deviation). Index
of the optical density of autoantibodies in relation to the negative control antiB13
values in stage III individuals were signiﬁcantly different from those in the
remaining groups. Analysis of variance F-ratio=24.58 (P<.001) (Student-
Newman-Keuls test for all pairwise comparisons, P<.05). CCD, chronic Chagas
disease; CG, control group; IODN, index of the optical density of autoantibodies
in relation to the negative control.
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Figure 2. Levels of index of the optical density of autoantibodies in relation to
the negative control of anti-B13 according to pathological echocardiographic
signs. I: normal echocardiogram, II: apical-septal hypokinesis, III: concentric
ventricular hypertrophy, IV: left atrial enlargement and abnormal
left ventricular relaxation with diastolic heart failure, V: globally dilated
cardiomyopathy with reduced ejection fraction; IODN, index of the optical
density of autoantibodies in relation to the negative control. Lines represent
the median (standard deviation). Patients with dilated cardiomyopathy and
reduced ejection fraction had a statistically signiﬁcantly increased level of
index of the optical density of autoantibodies in relation to the negative control
compared with those lacking this alteration. Analysis of variance F ratio=61.91
(P<.001) (Student-Newman-Keuls test for all pairwise comparisons, P<.05).
Table 1
Characteristics of Chronic Chagas Disease Patients by Group
Chronic Chagas heart disease P
I (n=30) II (n=25) III (n=25) Control group (n=10)
Age 49.7 (12) 53.5 (11) 58.4 (8) 61.1 (5) .012a
Gender, %
Male 30 48 48 60 NS
Female 70 52 52 40
Systolic blood pressure, mmHg 120 (11) 130 (10) 130 (10) 130 (10) .0042b
Diastolic blood pressure, mmHg 80 (10) 80 (10) 90 (10) 90 (10) .3
Risk of death score, %
High risk — — 100 Non aplicable < .001c
Low risk 100 100 —
Heart failure, % 0 0 100 100 < .001d
Left ventricular ejection fraction, % 51.2 (9.83) 48.35 (10.7) 38.1 (8.65) 40.2 (6.83) .03e
Antibodies
IODN-p2b 1.833 (1.03) 1.806 (1.145) 2.178 (1.310) 0.719 (0.243) .001f
IODN-B13 4.797 (2.333) 5.634 (2.056) 9.388 (2.505) 0.687 (0.136) < .001g
CCD, chronic Chagas disease; IODN, index of the optical density of autoantibodies in relation to the negative control; NS, not signiﬁcant.
Quantitative variables are expressed as means (standard deviation) and qualitative variables as proportions and percentages.
a CCD III and control group are different from CCD I and CCD II.
b CCD I is different from CCD II, CCD III and CG.
c CCD III is different from CCD I and CCD II.
d CCD III is different from CCD I and CCD II.
e CCD III and control group are different from CCD I and CCD II.
f Control croup is different from other groups.
g CCD III is different from other groups.
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anti-B13. The Wald criterion demonstrated that only IODN anti-
B13 signiﬁcantly contributed to prediction (odds ratio=2; 95%
conﬁdence interval [95%CI], 1.501-3.430; P=.0002), which was
linearly-related (Table 2). We also calculated the receiver
operating characteristic curve of IODN anti-B13 yielding an area
under the curve of 0.87% (P<.001) for an IODN anti-B13 of 6.655,
with a sensitivity of 99% (95%CI: 78.2-99.0) and a speciﬁcity of
74.58% (95%CI: 61.6-85.0) (Fig. 3).
DISCUSSION
The autoimmune response against myocardial antigens may
play a role in the development of severe forms of CCD.16 In the
present study, we assessed the inﬂuence of molecular mimicry
in promoting autoimmune antibody response in patients with
cardiopathy.
As an additional aim related to the autoantibody analysis, we
evaluated whether Na+/K+ pump ATPase of T. cruzi induced an
autoimmune reaction. These autoantibodies have not previously
been investigated in patients with Chagas disease, but their
presence has been detected in other myocardiopathy patients. We
hypothesized that these autoantibodies might be induced by
parasitic infection based on a previously reported phylogenetic
analysis indicating that type IIC Na+/K+ and H+/K+ ATPases of
organisms from different kingdoms have conserved sequences
excluding the highly variable N-terminal and C-terminal regions.41
We were unable to ﬁnd antibodies against the protein of the
parasite cationic pump in any of the patients with Chagas disease.
Although the parasite must express this pump to survive inside of
the host cell,31 it is apparent that the immunogenicity of this
antigen and/or the amount of the antigen and/or the routes of
antigenic presentation do not trigger the proliferation of B cell
clones against this antigen in T. cruzi human infection. As such, this
antigen may not be involved in the mimicry-driven production of
autoantibodies.
Among autoantibodies promoted by the parasite antigens, anti-
p2b and anti-B13 are the best characterized. These antibodies
have been found in the sera of experimentally infected animals
and patients with Chagas disease.16,27,42 Some studies suggest
that these antibodies may induce functional and structural
alterations of the cardiac tissue during experimental Chagas
disease.9,17–24,43,44 In addition, our results showed that individuals
with CCD had antibodies against peptide sequences of both
adrenergic receptor and cardiac myosin. Anti-p2b was present in
the entire study population, showing no between-group differ-
ences and being unrelated to clinical manifestations; these results
are consistent with those of other studies. Talvani et al.26 found no
correlation between anti-p2b and different CCD stages, but these
authors used a small sample size. Brenie`re et al.25 also found no
association between anti-p2b levels and electrocardiogram
changes, although patients with heart failure were not included
in the study. In the present study, the degree of pathological
echocardiographic signs, electrocardiographic conduction distur-
bances and heart failure showed no relationship with levels of anti-
p2b antibodies. Concerning anti-B13, Cunha-Neto et al.27 reported
that cardiac myosin–B13 cross-reactive antibodies were present in
all Chagas patients with heart failure, but only in 14% of
asymptomatic T. cruzi seropositive individuals. All the patients
serologically-positive for Chagas disease included in our study had
anti-B13 antibodies, as reported previously,45 and their levels were
signiﬁcantly higher in CCD stage III patients. In addition, the
comparison of the level of anti-B13 in relation to the pathological
echocardiographic signs showed that these autoantibodies in-
crease as structural cardiac involvement progresses.
CONCLUSION
Our results reﬂect an important correlation between the level of
anti-B13 autoantibodies and symptomatic heart failure and
pathological signs on echocardiography, suggesting that these
antibodies may be involved in disease progression. However,
longitudinal studies are needed to ascertain whether anti-B13
autoantibodies may have a predictive value in CCD.
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Table 2
Summary of Variables and Odd Ratios
Variables OR (95%CI) P
Age 1.04 (0.97-1.12) .2
Gender
Male 0.53 (0.08-3.35) .5
Female 1.88 (0.29-11.93) .5
Hypertension 1.10 (0.19-6.64) .9
Smoking 1.65 (0.16-16.26) .6
Alcohol consumption 0.52 (0.06-4.00) .5
Antibodies
IODN-p2b 0.80 (0.57-1.10) .1
IODN-B13 2.00 (1.50-3.43) .0002
95%CI, 95% conﬁdence interval; IODN, index of the optical density of autoantibodies
in relation to the negative control; OR: odds ratio.
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Figure 3. Receiver operating characteristic curve of index of the optical density of
autoantibodies in relation to the negative control anti-B13 as a serological
marker of chronic Chagas disease stage III. Area under the curve of 0.87% (P<.001)
for index of the optical density of autoantibodies in relation to the negative
control of anti-B13 of 6.655. Sensitivity of 99% (95% conﬁdence interval: 78.2-
99.0) and speciﬁcity of 74.58% (95% conﬁdence interval: 61.6-85.0). IODN, index
of the optical density of autoantibodies in relation to the negative control.
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